Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
CHA University
CHA University
CHA University
AstraZeneca
National Institutes of Health Clinical Center (CC)
Peking University
Aarhus University Hospital
Eisai Inc.
Ankara Etlik City Hospital
National Health Research Institutes, Taiwan
AstraZeneca
AstraZeneca
Tata Memorial Centre
Mayo Clinic
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Shanghai Zhongshan Hospital
Institute of Liver and Biliary Sciences, India
Centre Hospitalier Universitaire de Nice
AstraZeneca
University of Nottingham
CHA University
Erasmus Medical Center
CHA University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Washington
Mayo Clinic
Royal Marsden NHS Foundation Trust